Screener
CG Oncology CGON EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from CG Oncology’s reported figures.
Based on trailing twelve months.
The source filing: CG Oncology’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336918
FAQ
- What is CG Oncology's EBITDA margin?
- CG Oncology (CGON) reported EBITDA margin of -4,008.7% in Q2 2026.
- How has CG Oncology's EBITDA margin changed year-over-year?
- CG Oncology's EBITDA margin increased by 85.9% year-over-year, from -28,509.6% to -4,008.7%.
- What is the long-term trend for CG Oncology's EBITDA margin?
- Over 2 years (2023 to 2025), CG Oncology's EBITDA margin has grown at a -58.5% compound annual growth rate (CAGR), from -27,170.6% to -4,686.4%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about CG Oncology's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude